The Phase II trial is designed to compare a four-week dose-ranging regimen of once-daily oral SP-333 (1mg, 3mg and 6mg) against placebo in patients taking opioid analgesics for
The Phase III trial showed that EYLEA 2mg in both treatment groups (dosed monthly or every two months), showed a sustained improvement from baseline in best corrected visual
ACEON is an angiotensin converting enzyme (ACE) inhibitor approved for the treatment of patients with high blood pressure (hypertension) and reduce the risk of heart attack in patients
The US Food and Drug Administration (FDA) had approved DALVANCE in May 2014 and it was the first drug to be approved as a Qualified Infectious Disease Product
The phase III trial will compare daratumumab in combination with bortezomib, melphalan and prednisone to bortezomib, melphalan and prednisone alone as front line treatment for patients who are
As part of the deal, Pfizer will make an upfront payment of $225m to InnoPharma and up to $135m of contingent milestone payments. The transaction, which is subject
The two-period Phase III trial consisted of six months of on-demand therapy only, followed by 12 months of routine prophylaxis with BeneFIX 100 IU/kg once-weekly. The open-label, non-randomized
The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy
Currently, Eliquis is approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion is a commonly used, effective method of converting atrial fibrillation
The new facility will be spread over 100,000ft² plot and the company will first begin work on an oral solid unit and thereafter set up manufacturing units for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.